We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Diagnostic Assay Identifies Which Species Patients with Fish Allergy Can Tolerate

By LabMedica International staff writers
Posted on 20 Sep 2022
Print article
Image: ALEX2 is a state-of-the-art multiplex ELISA test based on proven immunoassay chemistry and detection methods (Photo courtesy of Macro Array Diagnostics)
Image: ALEX2 is a state-of-the-art multiplex ELISA test based on proven immunoassay chemistry and detection methods (Photo courtesy of Macro Array Diagnostics)

Fish allergy is an immune hypersensitivity to proteins found in fish. Symptoms can be either rapid or gradual in onset. The latter can take hours to days to appear. The former may include anaphylaxis, a potentially life-threatening condition which requires treatment with epinephrine.

Diagnostic tests for fish allergy included skin-prick tests and blood antibody tests, which are used to check for the presence of an immune protein called an anti-parvalbumin antibody, which the body produces in response to a fish allergen. If the tests aren’t conclusive, an allergist may recommend an oral food challenge.

Allergy Specialists at the University Hospital St. Pölten (St. Pölten, Austria) and their colleagues investigated whether multiplex immunoglobulin E (IgE) testing reveals potentially tolerated fish through absence of IgE to parvalbumin (PV) and extracts from specific species. Sera from a cohort that comprised 263 patients (median age, 12 years; range, 1-65; 160 of whom were males) from Austria, China, Denmark, Luxembourg, Norway and Spain with a documented clinical history of fish allergy and confirmed sensitization to fish.

The team used a research version of the ALEX2 multiplex IgE quantification assay (Macro Array Diagnostics, Vienna, Austria). Specific IgE to PVs from 10 fish species (nine bony and one cartilaginous), and to extracts from seven species was quantified. The IgE signatures of individual patients and patient groups were analyzed using SPSS and R.

The scientists reported that up to 38% of the patients were negative to cod PV, the most commonly used molecule in fish allergy diagnosis. Forty-five patients (17%) tested negative to PVs, but positive to the respective fish extracts, underlining the requirement for extracts for accurate diagnosis. Between 60% (Spain) and 90% (Luxembourg) of the patients were negative to PV and extracts from ray, a cartilaginous fish, indicating its potential tolerance. Up to 21% of the patients were negative to at least one bony fish species. Of the species analyzed, negativity to mackerel emerged as the best predictive marker of negativity to additional bony fish, such as herring and swordfish.

The team also calculated the probability that all three IgE tests would be negative for a species if tolerance to other species is known. They found patients who are negative for tuna are 92% likely to be negative for ray and swordfish. Patients who are negative for mackerel are 93% likely to be negative for herring and ray and 86% likely to be negative for swordfish.

Tanja Kalic, PhD, and Heimo Breiteneder, PhD, a professor of pathophysiology, both study authors, said, “The most commonly used fish allergen in diagnosis is cod parvalbumin, Gad m 1. In the study up to 38% of fish-allergic patients, depending on country of origin, were negative to this molecule, clearly showing that additional parvalbumins from other fish species are required in order to avoid false-negative testing of patients.”

The authors concluded that parvalbumins and extracts from multiple fish species relevant for consumption should be used in fish-allergy diagnosis, which may help identify potentially tolerated species for individual patients. The study was published on August 21, 2022 in The Journal of Allergy and Clinical Immunology: In Practice.

Related Links:
University Hospital St. Pölten
Macro Array Diagnostics 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.